Eupraxia Pharmaceuticals filed its Form 6-K on November 4, 2025, reporting financial and operational results for the nine months ended September 30, 2025. The filing, certified by the CEO and CFO, confirmed no material weaknesses in the design of Internal Control over Financial Reporting (ICFR) based on the COSO 2013 Framework.
Financially, the company generated no operating revenue. The net loss widened to approximately \(21.9M, up from \)18.2M in the prior year period, contributing to an accumulated deficit of \((152.87M)\). Research and Development expenses increased to $13.46M.
Liquidity is
...